Business Segments Attovia Therapeutics, Inc.
Stocks
ATTO
US04987L1026
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
21:00:00 18/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 22.14 USD | -2.60% |
|
-1.73% | - |
| 09-16 | Attovia Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 10:00 AM | |
| 09-02 | Attovia Therapeutics Q2 Net Loss Widens | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
Gene Research and Development | ||
Development of Therapeutic Products in The Fields of Immune-Mediated Diseases | - | 1.35M |
Total Assets | 76.72M | 166M |
CAPEX | -1.77M | -2.31M |
EBT | -39.8M | -60.63M |
D&A | 313K | 804K |
Operating Income | -41.55M | -67.16M |
Net Income | -39.8M | -60.63M |
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
United States of America | - | 1.35M |
Total Assets | 76.72M | 166M |
D&A | 313K | 804K |
CAPEX | -1.77M | -2.31M |
Net Income | -39.8M | -60.63M |
EBT | -39.8M | -60.63M |
Operating Income | -41.55M | -67.16M |
- Stock Market
- Stocks
- ATTO Stock
- Financials Attovia Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
